Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Ionis Pharmaceuticals Inc (IONS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ionis Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
41.54 -0.01    -0.02%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
41.05
-0.49
-1.18%
17:47:15 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,065,939
  • Bid/Ask: 41.05 / 43.33
  • Day's Range: 41.42 - 42.01
Ionis Pharma 41.54 -0.01 -0.02%

Ionis Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Ionis Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

796

Equity Type

ORD

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Contact Information

Address 2855 Gazelle Court
Carlsbad, 92010
United States
Phone 760 931 9200
Fax -

Top Executives

Name Age Since Title
Joseph Klein 60 2005 Independent Director
Spencer Robert Berthelsen 69 2002 Independent Director
Joseph Loscalzo 70 2014 Independent Chairman of the Board
Joseph Harris Wender 77 1994 Lead Independent Director
Michael R. Hayden 71 2018 Independent Director
Allene Maria Diaz 58 2021 Independent Director
Joan Elizabeth Herman 68 2019 Independent Director
B. Lynne Parshall 70 1991 Senior Strategic Advisor & Director
Brett P. Monia 62 2012 Founder, CEO & Director
Michael J. Yang 61 2023 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IONS Comments

Write your thoughts about Ionis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Tullio Bressanello
Tullio Bressanello Oct 01, 2021 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s about this stock? Any new therapies are coming out?
Crim Jamer
Crim Jamer Oct 01, 2021 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
Bobo Müller
Bobo Müller Jun 09, 2021 12:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
Kurt Maxberry
Kurt Maxberry Jun 07, 2021 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Added 4000 at 34.4
Crim Jamer
Crim Jamer May 20, 2021 4:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice after market move!
Luke Sky
Luke Sky Apr 24, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
Crim Jamer
Crim Jamer Mar 22, 2021 5:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
Sean Landolt
Sean Landolt Sep 30, 2020 3:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this stock doesn't know what a green day looks like.
형진 조
형진 조 Sep 14, 2019 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ㅜㅜ~
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email